



Investment Plan for Europe | October 2019

JUNCKER PLAN: IMPACT

SECTOR FACTSHEET - RDI



HOW HAS THE JUNCKER PLAN BENEFITED RESEARCH, DEVELOPMENT AND INNOVATION?

Investing in research and innovation is investing in Europe's future. Around two-thirds of the continent's economic growth over the last decades has been driven by innovation. Europe produces one third of all high-quality scientific publications and holds a world leading position in industrial sectors. Now we need to bring this scientific excellence and innovation potential to the market. With the help of the right financial instruments, we can lift technology-driven innovation and enable European companies to keep up with digitisation and global megatrends such as artificial intelligence and robotics. The Juncker Plan allows the European Investment Bank to increase private and leverage public spending for innovation, making Europe fit for decades to come.



The European Fund for Strategic Investments (EFSI) can be used to finance projects in:

Projects in line
with Horizon
2020

Development of
new technologies
and processes

Academic
support and link
to industry

Knowledge
and technology
transfer



JUNCKER PLAN: IMPACT


EXAMPLES OF PROJECTS SUPPORTED BY THE JUNCKER PLAN

Artificial hearts: CARMAT



Carmat is a ground-breaking medical research and development company that has designed a total artificial heart with the aim of providing an alternative to a heart transplant with real organs for patients suffering from end-stage heart failure. A €30 million loan is helping to finance Carmat's clinical trials and increase its production capacity, transforming it from a research entity to a commercial one, with the hope of bringing the artificial heart to market in the near future.

Supporting innovation: HANSAMATRIX



Latvian tech start-up HansaMatrix has received €10 million in financing to expand its production capacity and boost its research and development activities. HansaMatrix develops electronic systems and services that are used in a wide range of areas such as imaging, medical equipment and manufacturing. HansaMatrix was the first private company in Latvia to receive direct financing from the EIB under the Juncker Plan.

Brain cancer treatment: MAGFORCE



A €35 million loan is supporting German medical device company MagForce to develop a new approach to treating the most aggressive type of brain cancer, glioblastoma. Its therapy makes it possible to combat the tumour from within, while sparing surrounding healthy tissue. Patients are already being treated successfully in Germany, and the financing is enabling MagForce to offer the treatment in more countries, with rollout in Poland already achieved.